Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)

Abstract Immune checkpoint inhibitors (ICIs) have changed the treatment landscape for patients with non-small cell lung cancer (NSCLC). In spite of durable responses in some patients, many patients develop early disease progression during the ICI treatment. Thus, early identification of patients wit...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xinghao Ai, Bo Jia, Zhiyi He, Junping Zhang, Minglei Zhuo, Jun Zhao, Zhe Wang, Jiexia Zhang, Zaiwen Fan, Xiaotong Zhang, Chong Li, Feng Jin, Ziming Li, Xia Ma, Hao Tang, Xiang Yan, Wei Li, Yuanyuan Xiong, Huan Yin, Rongrong Chen, Shun Lu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Publishing Group 2024-12-01
coleção:	Signal Transduction and Targeted Therapy
Acesso em linha:	https://doi.org/10.1038/s41392-024-02060-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!